Navigation Links
RPS Continues Expansion of Global Clinical, Regulatory, Medical, and Operational Leadership
Date:7/20/2011

Research). 

Debra Marshall has over 30 years of healthcare and pharmaceutical industry management experience and most recent served as Assistant Vice President, US Global Site Management for Pfizer (formerly Wyeth), where she was instrumental in building a high performing Site Management Organization and implementing enhanced Site Management strategies.

Lexy Kelley, MD brings strong experience in the design, implementation and medical oversight of clinical development programs for the treatment of Lupus as well as clinical research experience in hematology, infectious diseases, rheumatology and allergy.  Prior to joining RPS, she served as an Associate Medical Director at UCB Pharma.

Marguerite (Peggy) Doran has over 25 years of pharmaceutical industry experience, including 18 years of experience in contract negotiation and management, implementation of sourcing strategies, contract optimization and process improvements as well as vendor relationship management and governance programs.

"Because of our unique business model, RPS has achieved impressive growth rates that far exceed those in the late stage CRO marketplace," said Daniel M. Perlman, Chairman and CEO.  "The new additions to our organization are a key component of our continued focus on growth and innovation in support of the global biopharmaceutical and medical device industries."

About RPS

RPS provides comprehensive global Phase II-IV clinical development solutions to the Pharmaceutical, Biotechnology, Medical Device and Diagnostic industries.  By combining our highly experienced clinical research operations infrastructure with the industry's largest resourcing engines, RPS is uniquely positioned to offer our Customers a broad spectrum of outsourcing solutions. These solutions range from globally Embedded functional and cross-functional programs to enhanced global full-service solutions, and are powered by highly experienced project t
'/>"/>

SOURCE ReSearch Pharmaceutical Services, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Beardsworth Continues to Strengthen Oncology Operations
2. SeqWright Continues Expansion of Next-Generation Sequencing Capabilities
3. Fourth Annual Probiotics Grant Continues to Fuel Growth In Research
4. IGEN Networks Corp continues to build a world class advisory board, with the appointment of three new members
5. Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation
6. New Test Centre in India: TUV Rheinland Continues Worldwide Investment Programme for Solar Industry
7. Simbionix Continues its Global Expansion
8. O2h Continues to Support Senexis to Support Patent Filing Senexis Limited
9. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
10. NEVO(TM) Sirolimus-Eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve-Month Data
11. Dehaier Medical Systems Continues Product Line Expansion. Signs Exclusive Distribution Agreement with HEYER Medical for Respiratory Products in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Calif. , Sept. 30, 2014 FemCap ... women,s health announces its receipt of a patent No: ... menstrual cup has also received FDA clearance in the ... and the CE in Europe. This patent is related to ... with this issuance, the company is releasing FemmyCycle Teen, ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Lyme ... funder of Lyme disease research at universities, today announced ... focused on the identification, treatment and cure for Lyme ... had received the most applications in its history—over 20 ... , “While we were pleased to receive so many ...
(Date:9/30/2014)... UFP Technologies, a producer of ... recently introduced a custom insulated shipping container to ... new insulated shipper solves the issue of temperature ... Technologies’ BioShell is a universal storage container which ... and shipping. The insulated shipper keeps frozen BioShells ...
(Date:9/29/2014)... Each year in the US, ... attention. In the military, burn injury is a ... medical care. More than 800 service members sustained ... heal slowly, remain inflamed and often become infected, ... and functionally damaging. While developments in supportive care ...
Breaking Biology Technology:The FemmyCycle 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 3Faster Healing with Fewer Scars 2
... , ... ... ... ...
... ... with a Complete, Cloud-Enabled API for Developers , ... Westborough, Mass. (Vocus) March 4, 2010 -- This seminar details the fast-growing ... The free seminar will include lunch, discussion, and startup to Free Basic Account. , ...
... ... ... ... ...
Cached Biology Technology:OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009 2OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009 3GenomeQuest Hosting Seminar at X Gen Congress In San Diego 2GenomeQuest Hosting Seminar at X Gen Congress In San Diego 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 2Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 4Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 5Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 6Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 7Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 8Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 9Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 10Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 11Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 12Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 13Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 14Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 15Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 16Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 17Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 18Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 19Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 20Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 21Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 22Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 23Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 24Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 25Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 26Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 27Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 28Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 29Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 30Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 31Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 32
(Date:9/30/2014)... Having trouble getting pregnanteven with IVF? Here,s some hope: ... of The FASEB Journal , explains ... protein known as PAWP, which induced embryo development in ... of embryo development by the sperm cell during fertilization. ... represent a major paradigm shift in our understanding of ...
(Date:9/30/2014)... a suite of perilous threats in today,s ocean. ... climate change, fragile coral ecosystems are disappearing at ... some species of corals surrounding the island of ... in their tropical environment: coral guard-crabs. New research ... Marine Station scientist Seabird McKeon and the museum,s ...
(Date:9/29/2014)... species of gut bacteria called Clostridium ramosum , coupled ... The work is published this week in mBio , ... , A research team from the German Institute of ... gut bacteria including C. ramosum gained weight when ... C. ramosum were less obese even when consuming a ...
Breaking Biology News(10 mins):Synthetic sperm protein raises the chance for successful in vitro fertilization 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Gut bacteria promote obesity in mice 2
... varies dramatically according to whether the nurses leave the ... airflow in a "Nightingale" warda classic hospital ward design ... bedsby using tracer gases to simulate how airborne infections ... generally good when windows were left open, keeping the ...
... Male circumcision reduces the abundance of bacteria living on the ... protection against HIV, according to a study led by the ... a significant shift in the bacterial community or microbiome of ... online journal mBio . This international collaboration focused ...
... What do woolly mammoths wandering around the ancient ... do with predicting how species could respond to ... Maryland Center for Environmental Science,s Appalachian Laboratory, along ... the University of California-Merced, have received a three-year, ...
Cached Biology News:Energy efficiency could increase infection risks in hospital wards 2Energy efficiency could increase infection risks in hospital wards 3TGen-led study discovers dramatic changes in bacteria following male circumcision 2Scientists look to ancient past to better predict how species may respond climate change 2
SHEEP ANTI FLECAINIDE...
MOUSE ANTI HUMAN B-CELLS (FMC7):FITC Immunogen: HRIK cells - Human B-Lymphoblastoid line...
... are ideal for use in refrigerators, freezers, or liquid ... vibrant colors allow for color coding to project, user, ... drainage or promote cool air circulation. Supplied with 10 ... tubes. Box dimensions: 13 x 13 x ...
RABBIT ANTI BACTERIAL HISTIDASE...
Biology Products: